Company intelligence / Profile preview

AKSO Biopharmaceutical, Inc.

Los Angeles, California, United Statesaksobio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

AB001, an engineered high-affinity soluble BCMA decoy receptor, has demonstrated effectiveness in inhibiting Multiple Myeloma and Diffuse Large B Cell Lymphoma in preclinical studies with impressive safety profile in non-human primates[8][10]

Therapeutic areas: OncologyRare DiseasesImmunologyOtherNephrology
Modalities: Protein therapeuticsBispecific biologicsAntibody-drug conjugatesRecombinant fusion proteins
Industry: Biotech

Drug pipeline

3 assets

AB-1005

Phase 2

Indications: Parkinson's disease, Multiple System Atrophy

2 more assets in the full pipeline.

Request access →

Partnerships

Huadong Medicine (for AB002 in Asia-Pacific excluding Japan)Chime Biologics (CDMO services)

Beyond the preview

Go deeper on AKSO Biopharmaceutical, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKSO Biopharmaceutical, Inc..

Explore the full profile